TRT and Gynecomastia — Why Does Breast Tissue Grow During Testosterone Therapy?

In our article on TRT myths (hair loss, acne, gynecomastia), we devoted one section to gynecomastia — enough to debunk the most common myth ('every man on TRT will eventually grow breasts'), but far too short to answer the questions men actually ask once they've already noticed a change around the nipple. Is this definitely gland tissue, or just fat? Will it go away on its own, or does it need action? What treatment actually has evidence behind it, versus what's just forum wisdom? This article answers those questions — a deeper, practical guide to one specific problem, rather than another general roundup of side effects.

Before we go further, one clarifying sentence: if you're looking for an answer to 'will this definitely happen' and want to see real data on how common gynecomastia is relative to hair loss and acne, we lay that out in our article on TRT myths. Here, we assume the change has already appeared, or that you want to know exactly how to identify it and what to genuinely do about it — and we focus on that alone.

Aromatase is the enzyme that converts some circulating testosterone into estradiol — the main estrogen in both women and men. It's found primarily in fat tissue, but also in the liver, brain, bones, and breast tissue itself. In a man with normal body weight and physiological testosterone levels, this process runs constantly in the background and keeps estradiol within a narrow, low reference range — low enough that a healthy adult man's glandular breast tissue stays dormant for life, despite being anatomically almost identical to a woman's pre-pubertal breast tissue.

This is a key, often overlooked fact: a man's glandular breast tissue isn't some separate, 'male' structure resistant to estrogen — it's the same tissue, with the same estrogen receptors, as in women, just that in a man it stays essentially inactive for life, because it's never exposed to the estrogen concentrations typical of a woman's cycle. Estradiol, by binding estrogen receptors (mainly ERα) on the epithelial cells lining the breast gland's ducts, activates the same signaling pathways that, in a woman, drive breast development at puberty: epithelial cell proliferation, ductal growth, and fibrosis of the surrounding connective-tissue stroma. In a man on TRT, this same mechanism can be triggered if local or systemic estradiol crosses the threshold at which the breast's receptors start responding — a threshold that varies between individuals and isn't identical to the 'upper limit of the lab reference range'.

In practice, this means the estradiol test result alone — while important and worth monitoring — is never the only piece of the puzzle. A doctor assessing suspected gynecomastia looks jointly at: estradiol and testosterone levels (total and free), how fast the change is growing, its character on palpation, the duration and dose of therapy, and the presence of other factors that boost aromatization, such as a higher body-fat percentage or the use of drugs or substances affecting the hormonal balance. The simple fact that estradiol is 'within range' doesn't rule out that it's responsible for a noticeable breast change — lab reference ranges are wide population ranges, not a guarantee of symptom-free status for a given individual.

This is arguably the most important part of this article, because it answers the question men ask themselves most often, before even booking a doctor's visit: 'is what I'm feeling really glandular tissue?'. Distinguishing real gynecomastia (glandular tissue growth driven by estrogen) from pseudogynecomastia, also called lipomastia (simple fat deposition around the breast, unrelated to gland hormonal activity), has enormous practical importance — because these two conditions require completely different management, and one of them (fat) has nothing to do with estradiol and won't resolve with any hormonal intervention.

This is the difference that decides whether hormonal intervention makes sense at all, which is why it deserves its own discussion. Gynecomastia moves through stages of different biology as it develops — it isn't one fixed state — and the stage at which it's noticed and addressed largely determines whether the change will regress.

In the early phase (usually the first few months after the change appears), active growth of the gland's epithelial tissue dominates, driven by ongoing estrogenic stimulation. This is the phase where the tissue tends to be most tender and responds fastest to a change in the hormonal environment — lowering estradiol (through correcting the testosterone dose, fat loss, or, in warranted cases, pharmacological treatment) can halt further growth, and in some cases lead to partial or complete regression of the change. Over time, if the stimulation persists, the glandular tissue gradually undergoes fibrosis and hyalinization — the epithelium is largely replaced by dense, collagen-rich connective tissue. This remodeling is a structural process, not just a functional one, and fibrotic tissue no longer has the same ability to regress under a change in hormone levels alone that tissue in the early, active growth phase does.

Treating gynecomastia on TRT usually proceeds in increasing order of invasiveness — from the least to the most invasive options, depending on severity, duration, and whether the change is still in an active phase or already fibrosed.

If watchful waiting isn't enough or the change is growing, the first step is always to review and correct the therapy itself — checking the current estradiol and testosterone levels, assessing whether the dose is genuinely physiological, and adjusting it as needed through the treating doctor. This is a step many men try to skip, reaching straight for 'estrogen' medications — while in fact the most common, simplest cause of excessive aromatization is simply too high a testosterone dose relative to individual needs, which can be corrected without any additional drug.

When a dose correction isn't enough and the change is still in an active, unfixed phase, pharmacological treatment comes into play. The best-documented option is tamoxifen — a selective estrogen receptor modulator (SERM) that blocks estrogen receptors directly in breast tissue, without lowering the blood estradiol level itself (unlike aromatase inhibitors). It's used off-label for treating gynecomastia, but has a real, multi-year evidence base behind it.

The last, most invasive option is surgery — most often subcutaneous mastectomy (removing glandular tissue through a small incision, often combined with liposuction of the surrounding fat), reserved for cases of established, fibrosed gynecomastia that doesn't respond to hormonal or pharmacological treatment, and for situations where the change is a source of significant physical or psychological discomfort. This is a well-established procedure in plastic and general surgery, with a well-understood safety profile, but — like any surgery — it carries its own risks (scarring, asymmetry, healing complications) worth discussing directly with a surgeon before deciding.

Any newly noticed change in breast tissue in a man — on TRT or not — is reason enough to book a doctor's consultation, if only to confirm it really is therapy-related gynecomastia and not something else. There's no need to wait for the change to 'develop' or grow large enough to be uncomfortable — early assessment is cheaper, simpler, and, as the timeline section above shows, gives a genuinely better chance of full regression.

Gynecomastia on TRT is a problem that can genuinely be addressed — provided it's treated specifically, not in generalities. First establish what you're actually dealing with (self-exam plus, if in doubt, an ultrasound), then assess how long the change has been present and whether it's still in an active phase, and only then, together with a doctor, choose the appropriate level of intervention — from a simple dose correction, through tamoxifen, to surgery in established, fibrosed cases. The worst strategy is passive waiting combined with online self-diagnosis — because that's exactly the time window in which the change has a chance to move from a reversible glandular phase into permanent fibrous tissue, the window in which the simplest interventions work best.